about
Malignant melanoma (non-metastatic).Pituitary hCG production and cerebral tuberculosis mimicking disease progression during chemotherapy for an advanced ovarian germ cell tumourThe management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1).Haemoptysis from a pulmonary arteriovenous malformation in a post molar pregnancy gestational trophoblast tumour patient managed by radiological embolisation: a case reportThe demographics of molar pregnancies in England and Wales from 2000-2009.Successful treatment of metastatic hepatic epithelioid hemangioendothelioma with thalidomide: a case report.A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential.Development and economic trends in cancer therapeutic drugs: a 5-year update 2010-2014.All for CD91 and CD91 for all.Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study.Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia.A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily.Overdiagnosis of complete and partial hydatidiform mole in tubal ectopic pregnancies.Chemotherapy curable malignancies and cancer stem cells: a biological review and hypothesisThe place of VEGF inhibition in the current management of renal cell carcinoma.A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia.The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours.Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II studyA new approach to immunotherapy: for AIDS and AIDS-related malignancies.Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements.Partial molar pregnancy after intracytoplasmic sperm injection occurring as a result of diploid sperm usage.Meigs syndrome presenting with axillary vein thrombosis and lymphadenopathy: a case reportPractical issues in the management of low-risk gestational trophoblast tumors.Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.Mutations in NLRP7 and KHDC3L confer a complete hydatidiform mole phenotype on digynic triploid conceptions.Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.Atypical placental site nodule (APSN) and association with malignant gestational trophoblastic disease; a clinicopathologic study of 21 cases.Risk of recurrent molar pregnancies following complete and partial hydatidiform moles.Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review.Late spontaneous resolution of persistent molar pregnancy.Cancer referral and treatment activity 2010-2015: a population-based study from Vancouver Island.Uterine arteriovenous malformation: fertility-sparing surgery using unilateral ligation of uterine artery and ovarian ligament.Brain metastases in gestational trophoblast neoplasia: an update on incidence, management and outcome.The natural history and management of Merkel cell carcinoma of the skin: a review of 22 patients treated at the Royal Marsden Hospital.A recombinant single-chain antibody interleukin-2 fusion protein.Post-transplantation lymphoproliferative disease.Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause.A recombinant single chain antibody interleukin-2 fusion proteinTamoxifen is not detrimental to endothelial function in postmenopausal women with breast cancer.
P50
Q33448157-8E5387AA-49AD-46CA-9FA9-A43E81A1E184Q33619920-C19589EB-6D7D-4BD1-BA41-71EAB4A4FBECQ33708103-8AB90EB2-20D7-48CF-BB05-DB2248EF4B80Q33789254-CE8022AF-5FBA-4AF0-835F-9554B14C1E3DQ34134284-7C547C1E-2742-4E79-8224-F48003C98424Q34499046-D4F2A0C2-FA6A-44EC-9DA3-65878E9D177EQ34764827-7D913B65-F151-46EE-92D0-E0D986C31002Q35021459-8DE8B29A-966D-47E5-8F92-CF037BB87557Q35198347-F7862187-B533-4A39-8CDF-278300A183F4Q35600783-F5D12D5A-ABAC-41DD-A1BA-2E652C7BB32AQ35683406-6A950C0F-541C-4986-9969-1EA443058117Q35832400-BB85EC10-C922-4409-88D7-012D470738C4Q36136253-161531D0-19A4-4EE0-94D0-1654C4CE3914Q36169285-5EB78812-EC84-4526-8BF5-9EAFBD4253B5Q36200232-8E2A14BE-95F2-4EE4-905E-027121DBAFE3Q36409967-7FE8CEFB-B666-47F4-BFE6-76360BEE7CCFQ36610042-2247C29F-BEA4-41D7-8C49-90A7A96758B1Q36611886-B2B7EF52-273E-48E6-992F-D7A61A8D9D30Q36621976-CBFEF28B-D0B1-4BD3-961B-D0F640013CDAQ36854008-E1DDD0ED-CDFD-4145-BD50-67254547CD2FQ36876448-C0FB5EE3-1A42-43DF-981F-8A29EE0B4464Q36966418-7CB5AD36-4B23-440E-BE57-62C8C5B33DBFQ37112949-08767060-2C77-44B7-A52C-BCD4A7CC0917Q37323842-6C54799B-A0AA-4C61-873E-59CEA947D6E6Q37407181-B847B6B2-D0B0-4605-A5F5-026E9384BEE4Q38057715-362E6CDA-7352-4114-B5D9-DF0BC83FBF72Q38274384-46116755-4EF6-440A-83B9-B91A045F13CEQ38352957-CBF04058-CF7A-4DCA-9E21-3B6B3760D5D9Q38552547-EF268A02-5E3E-446B-B03E-11F49DD48A34Q38601318-137F9ACC-E0C2-44C4-B77D-C104729FEC93Q38698766-650E73D0-3919-4A18-858D-44C9E5B2BF1FQ38775086-A71B5F7A-F7CD-4F20-86AC-E4F88E64485BQ40232844-4F24E1C4-6410-4F54-996C-E2973A9582B4Q41565800-7B40DE52-7B2A-4B39-B682-6D675BA8365EQ41575845-E6263248-85AC-4607-8FFC-4B6CAB1FD0E2Q41587078-19C30E6F-2E36-41EB-843F-BC155F552749Q41609006-97582321-DB32-4017-A26D-D9E5CFA0E46CQ41641176-1206C5FE-F7BF-4272-8DFE-E394899312B7Q42390576-892E1EE5-175C-4917-99A3-50DFEEDC6A86Q43752583-5F594C86-F32B-4100-835D-EEBC38ACBA32
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Philip Savage
@ast
Philip Savage
@en
Philip Savage
@es
Philip Savage
@nl
Philip Savage
@sl
type
label
Philip Savage
@ast
Philip Savage
@en
Philip Savage
@es
Philip Savage
@nl
Philip Savage
@sl
prefLabel
Philip Savage
@ast
Philip Savage
@en
Philip Savage
@es
Philip Savage
@nl
Philip Savage
@sl
P106
P21
P31
P496
0000-0002-4792-6869